keyword
MENU ▼
Read by QxMD icon Read
search

Tedizolid

keyword
https://www.readbyqxmd.com/read/28061827/systematic-review-and-network-meta-analysis-of-tedizolid-for-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections-caused-by-mrsa
#1
Rachael McCool, Ian M Gould, Jacqui Eales, Teresa Barata, Mick Arber, Kelly Fleetwood, Julie Glanville, Teresa L Kauf
BACKGROUND: Tedizolid, the active moiety of tedizolid phosphate, is approved in the United States, the European Union, Canada and a number of other countries for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by certain susceptible bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). This network meta-analysis (NMA) evaluates the comparative effectiveness of tedizolid and other antibacterials indicated for the treatment of ABSSSI caused by MRSA...
January 7, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28053508/critical-role-of-tedizolid-in-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections
#2
REVIEW
Olivia Ferrández, Olatz Urbina, Santiago Grau
Tedizolid phosphate has high activity against the Gram-positive microorganisms mainly involved in acute bacterial skin and skin structure infections, such as strains of Staphylococcus aureus (including methicillin-resistant S. aureus strains and methicillin-sensitive S. aureus strains), Streptococcus pyogenes, Streptococcus agalactiae, the Streptococcus anginosus group, and Enterococcus faecalis, including those with some mechanism of resistance limiting the use of linezolid. The area under the curve for time 0-24 hours/minimum inhibitory concentration (MIC) pharmacodynamic ratio has shown the best correlation with the efficacy of tedizolid, versus the time above MIC ratio and the maximum drug concentration/minimum inhibitory concentration ratio...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28007722/physical-compatibility-of-isavuconazonium-sulfate-with-select-i-v-drugs-during-simulated-y-site-administration
#3
Wonhee So, Liz Kim, Abrar K Thabit, David P Nicolau, Joseph L Kuti
PURPOSE: The physical compatibility of isavuconazonium sulfate with 95 i.v. drugs during simulated Y-site administration was studied. METHODS: Isavuconazonium sulfate for injection and all other drugs were reconstituted according to the manufacturer's recommendation and further diluted with 0.9% sodium chloride injection or 5% dextrose injection to a final concentration (1.5 mg/mL for isavuconazonium sulfate and standard concentrations used clinically for other drugs)...
January 1, 2017: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/27970803/cost-minimization-analysis-of-tedizolid-for-the-treatment-of-acute-bacterial-skin-and-skin-sub-structure-infections-absssi-in-greece
#4
R Insinga, E Dalakaki, M P Retsa, A Karokis, E M Sarpong
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27941424/characterization-of-neurologic-and-ophthalmologic-safety-of-oral-administration-of-tedizolid-for-up-to-21-days-in-healthy-volunteers
#5
Edward Fang, Kelly A Muñoz, Philippe Prokocimer
BACKGROUND: Antibacterials that inhibit protein synthesis may be associated with mitochondrial toxicity, manifested as serious optic or peripheral neuropathy or myelosuppression. Tedizolid is a novel oxazolidinone antibacterial that may have reduced the potential for mitochondrial toxicity. STUDY QUESTION: Based on the results of 2 studies (NCT01623401 and NCT00671814) conducted early in the tedizolid development program, what is the potential for drug-induced optic and peripheral neuropathies with tedizolid treatment? METHODS: Two phase-1 studies were conducted in healthy volunteers...
November 15, 2016: American Journal of Therapeutics
https://www.readbyqxmd.com/read/27904526/new-agents-approved-for-treatment-of-acute-staphylococcal-skin-infections
#6
Jan Tatarkiewicz, Anna Staniszewska, Magdalena Bujalska-Zadrożny
Vancomycin has been a predominant treatment for methicillin-resistant Staphylococcus aureus (MRSA) infections for decades. However, growing reservations about its efficacy led to an urgent need for new antibiotics effective against MRSA and other drug-resistant Staphylococcus aureus strains. This review covers three new anti-MRSA antibiotics that have been recently approved by the FDA: dalbavancin, oritavancin, and tedizolid. The mechanism of action, indications, antibacterial activity profile, microbial resistance, pharmacokinetics, clinical efficacy, adverse effects, interactions as well as available formulations and administration of each of these new antibiotics are described...
December 1, 2016: Archives of Medical Science: AMS
https://www.readbyqxmd.com/read/27890418/comparative-in-vitro-activity-of-oritavancin-and-other-agents-against-methicillin-susceptible-and-methicillin-resistant-staphylococcus-aureus
#7
Debora Sweeney, Dean L Shinabarger, Francis F Arhin, Adam Belley, Greg Moeck, Chris M Pillar
Methicillin-resistant Staphylococcus aureus (MRSA) infections constitute a threat to the public health due to their prevalence and associated mortality and morbidity. Several agents have been recently approved to treat MRSA skin infections including lipoglycopeptides (dalbavancin, oritavancin, and telavancin), ceftaroline, and tedizolid. This study compared the MIC, minimum bactericidal concentration (MBC), and time-kill of these agents alongside daptomycin, linezolid, and vancomycin against MRSA (n=15); meropenem, cefazolin, and nafcillin were also included against methicillin-susceptible S...
February 2017: Diagnostic Microbiology and Infectious Disease
https://www.readbyqxmd.com/read/27889013/methicillin-resistant-staphylococcus-aureus-infections-a-review-of-the-currently-available-treatment-options
#8
REVIEW
S M Purrello, J Garau, E Giamarellos, T Mazzei, F Pea, A Soriano, S Stefani
This review is the result of discussions that took place at the 5th MRSA Working Group Consensus Meeting and explores the possible treatment options available for different types of infections due to methicillin-resistant Staphylococcus aureus (MRSA), focusing on those antibiotics that could represent a valid alternative to vancomycin. In fact, whilst vancomycin remains a viable option, its therapy is moving towards individualised dosing. Other drugs, such as the new lipoglycopeptides (oritavancin, dalbavancin and telavancin) and fifth-generation cephalosporins (ceftaroline and ceftobiprole), are showing good in vitro potency and in vivo efficacy, especially for patients infected with micro-organisms with higher vancomycin minimum inhibitory concentrations (MICs)...
December 2016: Journal of Global Antimicrobial Resistance
https://www.readbyqxmd.com/read/27873126/resistance-to-non-glycopeptide-agents-in-serious-staphylococcus-aureus-infections
#9
REVIEW
Kyle C Molina, Vanthida Huang
The role of vancomycin in the treatment of serious Staphylococcus aureus infections, both methicillin-susceptible and methicillin-resistant, is becoming increasingly ineffective due to increasing MIC and failure. The development of reduced vancomycin susceptibility by S. aureus to glycopeptides highlights the need for clinicians to reexamine the roles of non-glycopeptide therapy. As the use of these alternative non-glycopeptides antimicrobials increases, it will become pertinent to monitor the rates of resistance...
December 2016: Current Infectious Disease Reports
https://www.readbyqxmd.com/read/27866673/surveillance-of-tedizolid-activity-and-resistance-in-vitro-susceptibility-of-gram-positive-pathogens-collected-over-5-years-from-the-united-states-and-europe
#10
Mekki Bensaci, Daniel Sahm
In vitro activity of tedizolid and comparators against 11,231 Gram-positive clinical isolates from the United States (84 centers) and Europe (115 centers) were summarized as part of the Surveillance of Tedizolid Activity and Resistance program between 2009 and 2013. Susceptibility testing was performed according to Clinical Laboratory and Standards Institute (CLSI) guidelines. Minimum inhibitory concentration (MIC) interpretations were based on CLSI and European Committee on Antimicrobial Susceptibility Testing criteria...
February 2017: Diagnostic Microbiology and Infectious Disease
https://www.readbyqxmd.com/read/27855069/activity-of-tedizolid-in-methicillin-resistant-staphylococcus-epidermidis-experimental-foreign-body-associated-osteomyelitis
#11
Kyung-Hwa Park, Kerryl E Greenwood-Quaintance, Audrey N Schuetz, Jayawant N Mandrekar, Robin Patel
We developed a rat model of methicillin-resistant Staphylococcus epidermidis (MRSE) foreign body-associated osteomyelitis and used it to compare tedizolid alone and in combination with rifampin, against rifampin alone, vancomycin plus rifampin, and vancomycin alone. A clinical strain of MRSE was inoculated into the proximal tibia and a stainless-steel wire with precolonized MRSE biofilm was implanted. Following a one-week infection period, 92 rats received either no treatment (n=17) or 14 days of intraperitoneal tedizolid (n=15), tedizolid plus rifampin (n=15), rifampin (n=15), vancomycin plus rifampin (n=15), or vancomycin (n=15)...
November 14, 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27799200/comparative-in-vivo-efficacies-of-tedizolid-in-neutropenic-versus-immunocompetent-murine-streptococcus-pneumoniae-lung-infection-models
#12
Kamilia Abdelraouf, David P Nicolau
Given that tedizolid exhibits substantial lung penetration, we hypothesize that it could achieve good efficacy against Streptococcus pneumoniae lung infections. We evaluated the pharmacodynamics of tedizolid for treatment of S. pneumoniae lung infections and compared the efficacies of tedizolid human-simulated epithelial lining fluid (ELF) exposures in immunocompetent and neutropenic murine lung infection models. ICR mice were rendered neutropenic via intraperitoneal cyclophosphamide injections and then inoculated intranasally with S...
January 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27769972/physical-compatibility-of-tedizolid-phosphate-with-selected-i-v-drugs-during-simulated-y-site-administration
#13
Islam Ghazi, Yukihiro Hamada, David P Nicolau
PURPOSE: The physical compatibility of commonly used agents that could be coadministered in the clinical setting with tedizolid phosphate during Y-site administration was evaluated. METHODS: Tedizolid phosphate vials were reconstituted to a final concentration of 0.8 mg/mL. All other drugs were prepared according to manufacturers' recommendations and diluted with 0.9% sodium chloride injection (where applicable) to the highest standard concentrations used clinically...
November 1, 2016: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/27743684/-comparative-activity-of-tedizolid-against-clinical-isolates-of-linezolid-resistant-coagulase-negative-staphylococci-and-methicillin-resistant-staphylococcus-aureus
#14
Santiago Pérez-Parra, Alejandro Peña-Monje, Juan Luis Recio, Federico García-García
No abstract text is available yet for this article.
October 12, 2016: Enfermedades Infecciosas y Microbiología Clínica
https://www.readbyqxmd.com/read/27721280/in-vitro-activity-of-ceftaroline-a-novel-antibiotic-against-methicillin-resistant-staphylococcus-aureus
#15
Vaishali Gaikwad, Tejash Gohel, Shrijeet Panickar, Vijay Chincholkar, Santosh Mangalkar
INTRODUCTION: Staphylococcus is one of the most common causes of nosocomial infection, especially pneumonia, surgical site infections, blood stream infections, and continues to be a major cause of community-acquired infections. The emergence of penicillin resistance followed by the development and spread of strains resistant to the semisynthetic penicillins such as methicillin, oxacillin and nafcillin, macrolides, tetracycline, and aminoglycosides has made the treatment of staphylococcal infection a global challenge...
October 2016: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/27718751/tedizolid-in-skin-and-skin-structure-infections-brave-new-world
#16
P Panagopoulos, N Papanas, E Maltezos
No abstract text is available yet for this article.
October 10, 2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/27713022/the-underappreciated-in%C3%A2-vitro-activity-of-tedizolid-against-bacteroides-fragilis-species-including-strains-resistant-to-metronidazole-and-carbapenems
#17
Ellie J C Goldstein, Diane M Citron, Kerin L Tyrrell, Elisa S Leoncio, C Vreni Merriam
Because Bacteroides fragilis has the ability to develop mechanisms of resistance to almost all antibiotics, we studied the comparative in vitro activity of tedizolid against 124 Bacteroides group species clinical isolates, including carbapenem, metronidazole and piperacillin-tazobactam resistant strains. Tedizolid had an MIC90 of 2 μg/ml (range, 0.5-4 μg/ml) and was 1-4 times more active than linezolid that had an MIC90 of 8 μg/ml (range, 2-16 μg/ml). It was also active (MICs 0.5-2 μg/ml) against the 27 ertapenem, 2 metronidazole and 12 piperacillin-tazobactam resistant strains tested...
October 3, 2016: Anaerobe
https://www.readbyqxmd.com/read/27677280/in-vitro-activity-of-tedizolid-against-staphylococcus-aureus-and-streptococcus-pneumoniae-collected-in-2013-and-2014-from-sites-in-latin-american-countries-australia-new-zealand-and-china
#18
D J Biedenbach, S K Bouchillon, B Johnson, J Alder, D F Sahm
Tedizolid is an oxazolidinone with an antimicrobial in vitro potency advantage against Gram-positive bacterial pathogens compared to other currently marketed drugs in this class, including linezolid. Tedizolid was compared to linezolid when tested against Staphylococcus aureus and Streptococcus pneumoniae isolates collected from countries in Latin America and the Asia-Pacific. Isolates were tested by broth microdilution susceptibility methods against tedizolid, linezolid, and non-class comparators in accordance with the Clinical and Laboratory Standards Institute (CLSI) guidelines...
December 2016: European Journal of Clinical Microbiology & Infectious Diseases
https://www.readbyqxmd.com/read/27645240/in-vitro-and-in-vivo-activities-of-a-bi-aryl-oxazolidinone-rbx-11760-against-gram-positive-bacteria
#19
Tarani Kanta Barman, Manoj Kumar, Tarun Mathur, Tridib Chaira, G Ramkumar, Vandana Kalia, Madhvi Rao, Manisha Pandya, Ajay Singh Yadav, Biswajit Das, Dilip J Upadhyay, Hamidullah, Rituraj Konwar, V Samuel Raj, Harpal Singh
RBx 11760, a bi-aryl oxazolidinone, was investigated for antibacterial activity against Gram-positive bacteria. The MIC90s of RBx 11760 and linezolid against Staphylococcus aureus were 2 and 4 mg/liter, against Staphylococcus epidermidis were 0.5 and 2 mg/liter, and against Enterococcus were 1 and 4 mg/liter, respectively. Similarly, against Streptococcus pneumoniae the MIC90s of RBx 11760 and linezolid were 0.5 and 2 mg/liter, respectively. In time-kill studies, RBx 11760, tedizolid, and linezolid exhibited bacteriostatic effect against all tested strains except S...
December 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27599998/in-vitro-activities-of-tedizolid-compared-with-other-antibiotics-against-gram-positive-pathogens-associated-with-hospital-acquired-pneumonia-skin-and-soft-tissue-infection-and-bloodstream-infection-collected-from-26-hospitals-in-china
#20
Shuguang Li, Yu Guo, Chunjiang Zhao, Hongbin Chen, Bijie Hu, Yunzhuo Chu, Zhijie Zhang, Yunjian Hu, Zhiyong Liu, Yan Du, Qiaodi Gui, Ping Ji, Ji Zeng, Bin Cao, Quan Fu, Rong Zhang, Zhongxin Wang, Chao Zhuo, Xianju Feng, Wei Jia, Yan Jin, Xuesong Xu, Kang Liao, Yuxing Ni, Yunsong Yu, Xiuli Xu, Zhidong Hu, Jin-E Lei, Qing Yang, Hui Wang
To evaluate the in vitro antimicrobial activities of tedizolid, linezolid and other comparators against clinically significant Gram-positive cocci isolates from hospital-acquired pneumonia (HAP), skin and soft tissue infection (SSTI) and bloodstream infection (BSI), 2140 nonduplicate isolates (23.7 % isolated from HAP, 46.8 % from SSTI and 29.5 % from BSI) were consecutively collected in 26 hospitals in 17 cities across China during 2014. These pathogens included 632 methicillin-resistant Staphylococcus aureus, 867 methicillin-sensitive Staphylococcusaureus, 299 coagulase-negative Staphylococcus (CoNS), 104 Enterococcus faecalis, 99 Enterococcusfaecium, 13 Streptococcus pneumoniae, 23 α-haemolytic Streptococcus and 103 β-haemolytic Streptococcus...
October 2016: Journal of Medical Microbiology
keyword
keyword
15433
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"